- Bayer AG BAYRY won five consecutive jury verdicts in lawsuits alleging that his weed killer Roundup caused non-Hodgkin’s lymphoma.
- The company is fighting the remaining cases targeting its weed killer, Roundup. It has set aside about $16 billion for settlements.
- Bayer claims Roundup is safe to use and has cited regulatory reviews from the US Environmental Protection Agency and other regulators that found it not carcinogenic, Wall Street Journal reported.
- Bayer lost three studies between 2018 and 2019 submitted by Roundup users who said the product caused their cancer and the company failed to adequately warn of Roundup’s danger.
- In a recent interview, Bayer CEO Werner Baumann said the company’s victories in lawsuits in various jurisdictions over the past year have shifted the momentum in Bayer’s favour.
- According to the report, Bayer has resolved approximately 108,000 of a total of 141,000 Roundup claims. Legal analysts said the company’s recent litigation wins put Bayer in a stronger position to try to solve the remaining cases.
- One of the testifying experts commented that about 96% of the mutations found in non-Hodgkin lymphoma were due to naturally occurring random replication errors, supporting his argument that Roundup was not responsible for cancer.
- Price promotion: BAYRY shares closed up 3.28% at $12.15 on Tuesday.
- Photo via company
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
Read full story here https://www.benzinga.com/news/22/10/29150234/roundup-weedkiller-maker-bayer-won-five-consecutive-cases-shifting-momentum-in-bayers-favor